{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-028406","form_type":"8-K","ticker":"SKIN","cik":"0001818093","company_name":"SkinHealth Systems Inc.","filed_at":"2023-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.411295+00:00","generated_at":"2026-06-11T23:09:52.713842+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BeautyHealth Q2 net sales $117.5M (+13% YoY); net income $3.4M; reaffirms FY guidance","bullets":["Net sales $117.5M (+13% YoY); net income $3.4M; adjusted EBITDA margin 15.1%.","Reaffirms 2023 net sales and 2025 guidance; refines 2023 adj. EBITDA margin to 18%-19%.","Consumables net sales +34% YoY; delivery systems +1% (or +30% ex trade-ups).","APAC net sales +143% YoY (China +265%); partner LaserAway for Syndeo at 125+ locations.","FDA clearance for SkinStylus for facial acne scarring; AWS collaboration for generative AI."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-028406","json":"https://secwatch.observer/filing/0001628280-23-028406.json","markdown":"https://secwatch.observer/filing/0001628280-23-028406.md","text":"https://secwatch.observer/filing/0001628280-23-028406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023028406/0001628280-23-028406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023028406/skin-20230809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T23:09:52.713842+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2efbb67163dc6a8b39839501a69aa62ae0dedb39","claim":"SkinHealth Systems Inc. reported the second quarter ended June 30, 2023 results: revenue $117.5 million, net income $3.4 million. Guidance reaffirmed.","evidence_excerpt":"For the quarter, net sales of $117.5 million increased +13% year-over-year, or +32% excluding trade-ups, continuing a trend of double-digit quarterly growth. Net income was $3.4 million, and adjusted EBITDA margin was 15.1% for the quarter. On the momentum, the Company re-affirms its 2023 net sales and long-term 2025 financial guidance, and refines its 2023 adjusted EBITDA margin to a more precise 18%-19% range.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023028406/0001628280-23-028406-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$117.5 million"},{"label":"Net income","value":"$3.4 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}